Abstract: A method of immunizing a mammalian patient against infection by a bacterial pathogen involves administering a pertussis or Pseudomonas antigen to the mammalian patient. The pertussis antigen is least one of a chaperonin protein GroEL from Bordetella pertussis, or a fragment thereof; and an OmpA protein of Bordetella pertussis, or a fragment thereof. The Pseudomonas antigen is least one of a chaperonin protein GroEL from Pseudomonas aeruginosa, or a fragment thereof; and an OprF protein from Pseudomonas aeruginosa, or an OmpA-domain fragment thereof. The bacterial pathogen expresses a protein having at least 45% identity to the pertussis antigen. The bacterial pathogen may be a gram-negative bacteria. The bacterial pathogen may be a bacteria from a genus Escherichia, a genus Enterococcus, a genus Staphylococcus, a genus Klebsiella, a genus Acinetobacter, and a genus Enterobacter.

Abstract: A vaccine composition for intranasal administration includes a Bordetella pertussis antigen, and an effective adjuvant amount of a high molecular weight glucose polymer. The high molecular weight glucose polymer may be a beta-glucan. The Bordetella pertussis antigen may be an extracellular toxin, an adhesion protein, an outer membrane protein, a receptor protein, a fragment thereof, or a mixture thereof.

Abstract: A vaccine composition for intranasal administration includes a Bordetella pertussis antigen, and an effective adjuvant amount of a high molecular weight glucose polymer. The high molecular weight glucose polymer may be a beta-glucan. The Bordetella pertussis antigen may be an extracellular toxin, an adhesion protein, an outer membrane protein, a receptor protein, a fragment thereof, or a mixture thereof.